3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS
申请人:Kuo Gee-Hong
公开号:US20070265252A1
公开(公告)日:2007-11-15
The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.
[reaction: see text] A practical method for the synthesis of opticallyactive styrene oxides has been developed via formation of opticallyactive 2-chloro-1-phenylethanols generated by reductive transformation of ring-substituted 2-chloroacetophenones. The opticallyactive alcohols with up to 98% ee are obtainable from the asymmetric reduction of acetophenones with an S/C = 1000-5000 with a formic
[反应:见正文]通过形成由环取代的2-氯苯乙酮的还原转化而生成的光学活性的2-氯-1-苯基乙醇,已经开发了一种合成光学活性的苯乙烯氧化物的实用方法。ee高达98%的旋光性醇可通过将S / C = 1000-5000的苯乙酮与含有明确定义的手性Rh络合物CpRhCl [(R,R)- tsdpen]。
Iridium-Catalyzed Asymmetric Hydrogenation of Halogenated Ketones for the Efficient Construction of Chiral Halohydrins
Iridium‐catalyzedasymmetrichydrogenation of prochiral halogenated ketones was successfully developed to prepare various chiral halohydrins with high reactivities and excellent enantioselectivities under basic reaction condition (up to >99% conversion, 99% yield, >99% ee). Moreover, gram‐scale experiment was performed well in the presence of just 0.005 mol% (S/C=20 000) Ir/f‐amphox catalyst with 99%
Mild Homologation of Esters through Continuous Flow Chloroacetate Claisen Reactions
作者:Maximilian A. Ganiek、Maria V. Ivanova、Benjamin Martin、Paul Knochel
DOI:10.1002/anie.201810158
日期:2018.12.21
Claisen homologation is for the first time extended to bis‐chloromethylenation using dichloroacetic acid (DCA), thus giving access to under‐explored α,α′‐bis‐chloroketones. The use of flow conditions enables efficient generation and reaction of the unstable chloroacetate dianion intermediates, leading to unprecedented mild and scalable reaction conditions at an economical reagent stoichiometry (−10 °C, <1 min
Discovery of a Potent, Orally Bioavailable β<sub>3</sub> Adrenergic Receptor Agonist, (<i>R</i>)-<i>N</i>-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide
作者:Robert J. Mathvink、J. Samuel Tolman、Dawn Chitty、Mari R. Candelore、Margaret A. Cascieri、Lawrence F. Colwell、Liping Deng、William P. Feeney、Michael J. Forrest、Gary J. Hom、D. Euan MacIntyre、Randall R. Miller、Ralph A. Stearns、Laurie Tota、Matthew J. Wyvratt、Michael H. Fisher、Ann E. Weber
DOI:10.1021/jm000286i
日期:2000.10.1
possessing a substituted thiazole benzenesulfonamide pharmacophore that are potent human beta(3) agonists with excellent selectivity against other human beta receptor subtypes. Several of these compounds also exhibited an improved pharmacokinetic profile in dogs. For example, thiazole sulfonamide 2e (R = 4-F(3)C-C(6)H(4)) is a potent full beta(3) agonist (EC(50) = 3.6 nM, 94% activation) with >600-fold selectivity